Lung Squamous Cell Carcinoma Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting lung squamous cell carcinoma clinical trials across 13 countries. Studies span Phase 1, Phase 2. Top locations include Houston, Texas, United States, Fairfax, Virginia, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Lung Squamous Cell Carcinoma Trials at a Glance

7 actively recruiting trials for lung squamous cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Houston, Fairfax, and Boston. Lead sponsors running lung squamous cell carcinoma studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Second Xiangya Hospital of Central South University, and AstraZeneca.

Browse lung squamous cell carcinoma trials by phase

Treatments under study

About Lung Squamous Cell Carcinoma Clinical Trials

Looking for clinical trials for Lung Squamous Cell Carcinoma? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Squamous Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Ovarian CancerEndometrial CancerLung Adenocarcinoma+1 more
AstraZeneca506 enrolled60 locationsNCT05797168
Recruiting
Phase 1Phase 2

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Breast CancerOvarian CancerCervical Cancer+5 more
Terremoto Biosciences Inc.205 enrolled15 locationsNCT07109726
Recruiting
Phase 1

JMT106 Injection in the Treatment of Advanced Solid Tumors

Hepatocellular CarcinomaAdvanced Solid TumorLung Squamous Cell Carcinoma
Shanghai JMT-Bio Inc.200 enrolled1 locationNCT07275073
Recruiting
Phase 2

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

Lung Squamous Cell Carcinoma
Sichuan University114 enrolled6 locationsNCT06121505
Recruiting

Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

Lung Squamous Cell CarcinomaTumor MicroenvironmentNeoadjuvant Chemoimmunotherapy
Tang-Du Hospital40 enrolled1 locationNCT06436040
Recruiting

Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers

Lung CancerNon-small Cell Lung CancerLung Adenocarcinoma+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences60,000 enrolled1 locationNCT06255197
Recruiting

The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC

Lung Squamous Cell Carcinoma
Second Xiangya Hospital of Central South University50 enrolled1 locationNCT05778253